Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.

@article{Sablan2012DemonstrationOS,
  title={Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine.},
  author={Benjamin P Sablan and Dong Joon Kim and Nina G Barzaga and Wan Cheng Chow and Mong Cho and Sang Hoon Ahn and Seong Gyu Hwang and Ji Hyun Lee and Hamid Namini and William L. Heyward},
  journal={Vaccine},
  year={2012},
  volume={30 16},
  pages={2689-96}
}
Adults 40 years of age and older have been shown to be hypo-responsive immunologically to the currently available hepatitis B virus (HBV) vaccines. Three intramuscular doses of a Toll-like receptor 9 agonist, 1018 immunostimulatory sequence (1018 ISS) adjuvant, combined with recombinant hepatitis B surface antigen (HBsAg) demonstrated faster, superior, and more durable seroprotection than three doses of a licensed comparator HBV vaccine (Engerix-B(®)). This investigational vaccine, HBsAg-1018… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

Similar Papers

Loading similar papers…